Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14747044 | 0.98 | KIF11 (0.41) | KCNH2KIF11POLBALDH1A1PARP1 | |
| SCHEMBL14745564 | 0.97 | KIF11 (0.42) | KCNH2KIF11POLBALDH1A1PARP1 | |
| SCHEMBL14758613 | 0.91 | TLR9 (0.42) | KCNH2POLBALDH1A1PARP1USP2 | |
| SCHEMBL16577243 | 0.90 | CHRNA7 (0.41) | KCNH2KIF11POLBALDH1A1PARP1 | |
| SCHEMBL14745632 | 0.89 | KCNH2 (0.38) | KCNH2KIF11POLBALDH1A1MAPT | |
| SCHEMBL14745079 | 0.89 | KCNH2 (0.43) | KCNH2KIF11POLBALDH1A1MAPT | |
| SCHEMBL17594868 | 0.89 | KIF11 (0.38) | KCNH2KIF11ALDH1A1PARP1PARP2 | |
| SCHEMBL14745051 | 0.88 | KCNH2 (0.43) | KCNH2KIF11POLBALDH1A1MAPT | |
| SCHEMBL17594969 | 0.88 | KIF11 (0.39) | KCNH2KIF11ALDH1A1PARP1PARP2 | |
| SCHEMBL14745803 | 0.88 | DCTPP1 (0.40) | KCNH2KIF11POLBALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | claimed |
| WO-2016039936-A2 | MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-2750505-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| CN-103889223-A | Antibacterial compounds and methods for use | PTC THERAPEUTICS INC | 2014-06-25 | — | — | CN | claimed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2016039936-A2 | MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2750505-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| CN-103889223-A | Antibacterial compounds and methods for use | PTC THERAPEUTICS INC | 2014-06-25 | — | — | CN | disclosed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | KCNH2 3306/4885KIF11 4448/4885POLB 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.